Results 171 to 180 of about 2,897 (211)

A Comprehensive Physiologically Based Pharmacokinetic Framework of Ofloxacin: Predicting Disposition in Renal Impairment. [PDF]

Pharmaceutics
Zamir A, Rasool MF, Hussain I, Alsanea S, Alhabardi SA, Alqahtani F.   +5 more
europepmc   +1 more source

PBBM Considerations for Base Models, Model Validation, and Application Steps: Workshop Summary Report. [PDF]

Mol Pharm
Heimbach T, Musuamba Tshinanu F, Raines K, Borges L, Kijima S, Malamatari M, Moody R, Veerasingham S, Seo P, Turner D, Fang L, Stillhart C, Bransford P, Ren X, Patel N, Sperry D, Chen H, Rostami-Hodjegan A, Lukacova V, Sun D, Nguefack JF, Carducci T, Grimstein M, Pepin X, Jamei M, Stamatopoulos K, Li M, Sanghavi M, Tannergren C, Mandula H, Zhao Z, Ju TR, Wagner C, Arora S, Wang M, Rullo G, Mitra A, Kollipara S, Chirumamilla SK, Polli JE, Mackie C.   +40 more
europepmc   +1 more source

Machine learning to predict food effects during drug development: a comprehensive review. [PDF]

J Cheminform
Shah A, Bi F, Yang J.
europepmc   +1 more source

Using a PBPK Model Incorporating Lymphatic Absorption to Predict Food Effect, Multiple Dosing, and Hepatic Impairment of Cannabidiol. [PDF]

Clin Transl Sci
Qian L, Zhou Z.
europepmc   +1 more source

<i>In vitro</i> and <i>in vivo</i> correlation of injectable lipid-based nanomedicines: From dissolution to protein coronas. [PDF]

Mater Today Bio
Wang H, Wu X, Wang J, Wang X, Lu Y.
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling for Predicting Drug Levels After Bariatric Surgery: Vardenafil Exposure Before vs. After Gastric Sleeve/Bypass. [PDF]

Biomolecules
Porat D, Dukhno O, Cvijić S, Dahan A.
europepmc   +1 more source

Development of in vitro-in vivo correlation for establishing patient-centric quality standards of dissolution for lamotrigine extended-release tablets. [PDF]

Eur J Pharm Biopharm
Zidan A, Siddique AB, Shaklah M, Anand O, O'Connor T, Ashraf M.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report

Journal of Pharmaceutical Sciences, 2021
This workshop report summarizes the proceedings of Day 2 of a three-day workshop on "Current State and Future Expectations of Translational Modeling Strategies toSupportDrug Product Development, Manufacturing Changes and Controls". From a drug product quality perspective, physiologically based biopharmaceutics modeling (PBBM) is a tool to link ...
Neil, Parrott, Sandra, Suarez-Sharp, Filippos, Kesisoglou, Shriram M, Pathak, David, Good, Christian, Wagner, André, Dallmann, James, Mullin, Nikunjkumar, Patel, Arian Emami, Riedmaier, Amitava, Mitra, Kimberly, Raines, James, Butler, Maziar, Kakhi, Min, Li, Yang, Zhao, Eleftheria, Tsakalozou, Talia, Flanagan, Jennifer, Dressman, Xavier, Pepin   +19 more
openaire   +4 more sources

Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development

Pharmaceutical Research, 2022
Physiologically based biopharmaceutics modeling (PBBM) emphasizes the integration of physicochemical properties of drug substance and formulation characteristics with system physiological parameters to predict the absorption and pharmacokinetics (PK) of a drug product.
Di Wu, Min Li
openaire   +4 more sources

Pulmonary drug absorption and systemic exposure in human: Predictions using physiologically based biopharmaceutics modeling

European Journal of Pharmaceutics and Biopharmaceutics, 2020
Systemic exposure of inhaled drugs is used to estimate the local lung exposure and assess systemic side effects for drugs with local pharmacological targets. Predicting systemic exposure is therefore central for successful development of drugs intended to be inhaled.
Johanna, Eriksson, Helena, Thörn, Hans, Lennernäs, Erik, Sjögren   +3 more
openaire   +4 more sources